AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18439113 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone
Number of subjects: 21
Study 17142146 — intervention group
Group type: COMPARATOR
Intervention: ezetimibe 10 mg daily with placebo colesevelam HCl twice daily (E)
Number of subjects: 20
Study 17142146 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg daily with 1.875 g colesevelam HCl twice daily (E + C)
Number of subjects: 20
Study 12663600 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg (A10)
Number of subjects: 217
Study 12663600 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (A80)
Number of subjects: 217
Study 12663600 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 217
Study 12663600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 10873879 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-L exchanges
Number of subjects: 82
Study 10873879 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-L exchanges
Number of subjects: 82
Study 10873879 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 daily 2-L exchanges)
Number of subjects: 82
Study 9110103 — intervention group
Group type: EXPERIMENTAL
Intervention: meta‐chlorophenylpiperazine (m‐CPP)
Number of subjects: 10
Study 9110103 — intervention group
Group type: COMPARATOR
Intervention: identical placebo capsules
Number of subjects: 10
Study 8249364 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (rhEpo) 6 x 10,000 U administered 4 and 2 weeks before surgery
Number of subjects: 49
Study 8249364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhEpo)
Number of subjects: 49
Study 8249364 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (rhEpo)
Number of subjects: 49
Study 3900456 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS-19-Q.GC tablet (TMS) at a dosage of 600 mg daily
Number of subjects: 218
Study 3900456 — intervention group
Group type: COMPARATOR
Intervention: Midecamycin (MDM) at a dosage of 1200 mg daily
Number of subjects: 218
Study 3900456 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS-19-Q.GC tablet (TMS)
Number of subjects: 218
Study 3900456 — intervention group
Group type: COMPARATOR
Intervention: Midecamycin (MDM)
Number of subjects: 218
Study 31846475 — intervention group
Group type: EXPERIMENTAL
Intervention: COR-1 (1 mg DNA administered intradermally as two injections of 500 μg each)
Number of subjects: 44
Study 31846475 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered intradermally as two injections of 500 μg each)
Number of subjects: 44
Study 29431027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheng-Yu-Tang (Chinese herbal formula) for up to 6 months
Number of subjects: 18
Study 29431027 — intervention group
Group type: COMPARATOR
Intervention: Standard-care treatment administered by their oncologist
Number of subjects: 18
Study 25901734 — intervention group
Group type: EXPERIMENTAL
Intervention: F2R rs168753 minor allele
Number of subjects: 503
Study 25901734 — intervention group
Group type: EXPERIMENTAL
Intervention: P2RY12 rs6809699 minor allele
Number of subjects: 503
Study 24189254 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg single-dose primaquine (PMQ)
Number of subjects: 28
Study 24189254 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/kg daily for 14 days
Number of subjects: 28
Study 24189254 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg twice daily
Number of subjects: 28
Study 24189254 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg 7-day PMQ regimen
Number of subjects: 28
Study 22922489 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (IM) therapy in early chronic phase (ECP)
Number of subjects: 189
Study 22922489 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (IM) therapy in late chronic phase (LCP)
Number of subjects: 189
Study 22922489 — intervention group
Group type: COMPARATOR
Intervention: Interferon (IFN)‐alpha‐2 followed by crossover to IM in late chronic phase (LCP)
Number of subjects: 189
Study 20799042 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual endurance training supplemented with heavy strength training twice a week during a 12-week preparatory period followed by strength maintenance training once a week during the first 13 weeks of a competition period (E + S)
Number of subjects: 12
Study 20799042 — intervention group
Group type: COMPARATOR
Intervention: Usual endurance training during the whole intervention period (E)
Number of subjects: 12
Study 18003562 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia medication (verum)
Number of subjects: 0
Study 18003562 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 16331754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegsunercept 800 microg/kg
Number of subjects: 194
Study 16331754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegsunercept 400 microg/kg
Number of subjects: 194
Study 16331754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 17642022 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, individualized education on pressure ulcer prevention (4 hours)
Number of subjects: 41
Study 17642022 — intervention group
Group type: COMPARATOR
Intervention: Standard education (control group)
Number of subjects: 41
Study 17642022 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 41
Study 9467549 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2; 0.1 mg every 3.5 days; n = 48)
Number of subjects: 97
Study 9467549 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (1.25 mg every day; n = 49)
Number of subjects: 97
Study 9467549 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2)
Number of subjects: 97
Study 9467549 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens
Number of subjects: 97
Study 9467549 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) and Oral conjugated equine estrogens
Number of subjects: 97
Study 7894856 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibrated GHQ
Number of subjects: 1000
Study 7894856 — intervention group
Group type: EXPERIMENTAL
Intervention: CES-D
Number of subjects: 1000
Study 7894856 — intervention group
Group type: EXPERIMENTAL
Intervention: CIDI
Number of subjects: 1000
Study 2650011 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 23
Study 2650011 — intervention group
Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 23
Study 30099716 — intervention group
Group type: EXPERIMENTAL
Intervention: FOB‐PDT (fibre optic bronchoscopy-guided percutaneous dilatational tracheostomy)
Number of subjects: 90
Study 30099716 — intervention group
Group type: COMPARATOR
Intervention: PDT (percutaneous dilatational tracheostomy)
Number of subjects: 90
Study 28926415 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 42
Study 28926415 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline confrontation naming
Number of subjects: 42
Study 28926415 — intervention group
Group type: EXPERIMENTAL
Intervention: Category fluency
Number of subjects: 42
Study 28926415 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic recognition
Number of subjects: 42
Study 28926415 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of semantic recognition and semantic naming
Number of subjects: 42
Study 28926415 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic-lexical retrieval factor
Number of subjects: 42
Study 28926415 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline semantic memory tests
Number of subjects: 42
Study 26141837 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 98
Study 26141837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 23302662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pattern with high loading values of vegetables and vegetable oils
Number of subjects: 2031
Study 23302662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pattern reflecting a high n-6:n-3 fatty acid intake ratio
Number of subjects: 2031
Study 21679511 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous methylprednisolone
Number of subjects: 40
Study 21679511 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg intravenous methylprednisolone
Number of subjects: 40
Study 21679511 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 40
Study 18295436 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive-behavioral therapy (ICBT)
Number of subjects: 197
Study 18295436 — intervention group
Group type: COMPARATOR
Intervention: Twelve-step facilitation
Number of subjects: 197
Study 16632012 — intervention group
Group type: EXPERIMENTAL
Intervention: High-hemoglobin group (target 13 to 15 g/dL)
Number of subjects: 195
Study 16632012 — intervention group
Group type: COMPARATOR
Intervention: Low-hemoglobin group (target 11 to 12 g/dL)
Number of subjects: 195
Study 16632012 — intervention group
Group type: EXPERIMENTAL
Intervention: High-hemoglobin group
Number of subjects: 195
Study 16632012 — intervention group
Group type: COMPARATOR
Intervention: Low-hemoglobin group
Number of subjects: 195
Study 14669415 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic metroplasty
Number of subjects: 31
Study 14669415 — intervention group
Group type: COMPARATOR
Intervention: Strassman's operation
Number of subjects: 31
Study 10953488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic polypectomy
Number of subjects: 181
Study 10953488 — intervention group
Group type: COMPARATOR
Intervention: Fractional curettage
Number of subjects: 181
Study 8995474 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 300 mg I/ml
Number of subjects: 20
Study 8995474 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 400 mg I/ml
Number of subjects: 20
Study 1638251 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed appointments with option to change time
Number of subjects: 1200
Study 1638251 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed appointments requiring telephoned confirmation of intention to attend
Number of subjects: 1200
Study 1638251 — intervention group
Group type: EXPERIMENTAL
Intervention: Open invitations inviting recipient to telephone to make an appointment
Number of subjects: 1200
Study 1638251 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 1200
Study 6387210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release propranolol (LA)
Number of subjects: 10
Study 6387210 — intervention group
Group type: COMPARATOR
Intervention: Conventional propranolol (Prop)
Number of subjects: 10
Study 30139835 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Tivantinib (T+E)
Number of subjects: 996
Study 30139835 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib plus Placebo (P+E)
Number of subjects: 996
Study 28092139 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT)
Number of subjects: 46
Study 28092139 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT)
Number of subjects: 46
Study 26333375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 36
Study 26333375 — intervention group
Group type: COMPARATOR
Intervention: Permanent polymer everolimus-eluting stent (PP-EES)
Number of subjects: 36
Study 22897595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantharidin
Number of subjects: 29
Study 22897595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 22115704 — intervention group
Group type: EXPERIMENTAL
Intervention: pemetrexed-cisplatin
Number of subjects: 3467
Study 22115704 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine-cisplatin
Number of subjects: 3467
Study 20662805 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 30 mg/d
Number of subjects: 80
Study 20662805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17699309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 75
Study 17699309 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 75
Study 14583363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bail-out stenting after unsuccessful balloon angioplasty
Number of subjects: 1044
Study 14583363 — intervention group
Group type: COMPARATOR
Intervention: Routine stenting
Number of subjects: 1044
Study 14583363 — intervention group
Group type: COMPARATOR
Intervention: Successful balloon angioplasty
Number of subjects: 1044
Study 10878704 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress echocardiography
Number of subjects: 173
Study 10878704 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress echocardiography in hypertensive group
Number of subjects: 173
Study 10878704 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress echocardiography in normotensive group
Number of subjects: 173
Study 9364675 — intervention group
Group type: EXPERIMENTAL
Intervention: S-L* (yeast-derived recombinant hepatitis B virus vaccine containing surface antigen and selected preS1 and preS2 sequences)
Number of subjects: 32
Study 9364675 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B (vaccine containing surface antigen alone)
Number of subjects: 32
Study 9364675 — intervention group
Group type: COMPARATOR
Intervention: Both S-L* and Engerix-B
Number of subjects: 32
Study 1424027 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic antegrade blood cardioplegia (n = 25)
Number of subjects: 74
Study 1424027 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic retrograde blood cardioplegia (n = 23)
Number of subjects: 74
Study 1424027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cold antegrade blood cardioplegia (n = 26)
Number of subjects: 74
Study 1424027 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm antegrade cardioplegia
Number of subjects: 74
Study 1424027 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm retrograde cardioplegia
Number of subjects: 74
Study 1424027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cardioplegia
Number of subjects: 74
Study 4065106 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone, 10 mg
Number of subjects: 10
Study 4065106 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine, 0.6 mg (given at peak effect of domperidone)
Number of subjects: 10
Study 4065106 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine, 0.6 mg
Number of subjects: 10
Study 4065106 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (after atropine)
Number of subjects: 10
Study 31791962 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 150
Study 29770163 — intervention group
Group type: EXPERIMENTAL
Intervention: PDRN prolotherapy
Number of subjects: 32
Study 26498973 — intervention group
Group type: EXPERIMENTAL
Intervention: Task‐Specific Checklist
Number of subjects: 3
Study 26498973 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Rating Scale
Number of subjects: 3
Study 26498973 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater and intra-rater reliability
Number of subjects: 3
Study 24767265 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 43
Study 24767265 — intervention group
Group type: COMPARATOR
Intervention: Healthy Topics (HT)
Number of subjects: 43
Study 22453754 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 2754
Study 22453754 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 2754
Study 21124125 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular cadaveric dermis (AlloDerm)
Number of subjects: 20
Study 21124125 — intervention group
Group type: COMPARATOR
Intervention: Native subpectoral capsule (internal control)
Number of subjects: 20
Study 17545350 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised decision aid
Number of subjects: 109
Study 17545350 — intervention group
Group type: COMPARATOR
Intervention: Guidelines arm (Control)
Number of subjects: 109
Study 17015999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin therapy (6 g/day)
Number of subjects: 0
Study 17015999 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin therapy (1 g/day)
Number of subjects: 0
Study 12787040 — intervention group
Group type: EXPERIMENTAL
Intervention: OSF mucosa
Number of subjects: 59
Study 12787040 — intervention group
Group type: COMPARATOR
Intervention: Normal oral mucosa (NOM)
Number of subjects: 59
Study 12787040 — intervention group
Group type: COMPARATOR
Intervention: Friction hyperkeratosis on OSF buccal mucosa (FHOSF)
Number of subjects: 59
Study 12787040 — intervention group
Group type: COMPARATOR
Intervention: Oral leukoplakia on OSF buccal mucosa (OLOSF)
Number of subjects: 59
Study 11015032 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 8.03 mg
Number of subjects: 192
Study 11015032 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 16.06 mg
Number of subjects: 192
Study 11015032 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 50 mg
Number of subjects: 192
Study 11015032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 9382431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing (yearly)
Number of subjects: 0
Study 9382431 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-in-a-lifetime sigmoidoscopy at 55-60 years of age
Number of subjects: 0
Study 9382431 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection of the oral cavity and pharynx with flexible endoscopy and blue-toluidine staining
Number of subjects: 0
Study 1420743 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg by sublingual route 5 min before the meal)
Number of subjects: 11
Study 1420743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine (20 mg by sublingual route 30 min before the meal)
Number of subjects: 11
Study 1420743 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 11
Study 3900458 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS-19-Q.GC tablet (600 mg daily)
Number of subjects: 265
Study 3900458 — intervention group
Group type: COMPARATOR
Intervention: Josamycin (1,200 mg daily)
Number of subjects: 265
Study 31694677 — intervention group
Group type: EXPERIMENTAL
Intervention: Image fusion group utilizing 3D preoperative planning and image fusion system
Number of subjects: 42
Study 31694677 — intervention group
Group type: COMPARATOR
Intervention: Control group utilizing only 3D preoperative planning
Number of subjects: 42
Study 29486321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 0
Study 29486321 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 27831987 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for proximal junctional failure (PJF) or clinically significant proximal junctional kyphosis (PJK) based on demographic, radiographic, and surgical factors.
Number of subjects: 510
Study 27831987 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors included age, lower‐most instrumented vertebra (LIV), pre‐operative sagittal vertical axis (SVA), upper‐most instrumented vertebra (UIV) implant type, UIV, pre‐operative pelvic tilt (PT), and pre‐operative pelvic incidence minus lumbar lordosis (PI-LL).
Number of subjects: 510
Study 27831987 — intervention group
Group type: EXPERIMENTAL
Intervention: PJF defined as requiring revision for PJK.
Number of subjects: 510
Study 25179849 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aggressive therapy
Number of subjects: 48
Study 22870185 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 5098
Study 22870185 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and blood pressure
Number of subjects: 5098
Study 22870185 — intervention group
Group type: COMPARATOR
Intervention: Fasting glucose and 2 h OGTT
Number of subjects: 5098
Study 20331668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 92
Study 20331668 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 92
Study 18026680 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Mental Health Care (IA)
Number of subjects: 709
Study 18026680 — intervention group
Group type: COMPARATOR
Intervention: Control Area (CA)
Number of subjects: 709
Study 16378115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg/kg administered before rebeat
Number of subjects: 20
Study 16378115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 20
Study 11833860 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g sodium oxybate
Number of subjects: 136
Study 11833860 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g sodium oxybate
Number of subjects: 136
Study 11833860 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g sodium oxybate
Number of subjects: 136
Study 11833860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 10416249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (10, 100, 500, 1000 micrograms/m3)
Number of subjects: 0
Study 10416249 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde (5000 micrograms/m3)
Number of subjects: 0
Study 10416249 — intervention group
Group type: COMPARATOR
Intervention: Synthetic air (control)
Number of subjects: 0
Study 7737713 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of 25 mg hydrochlorothiazide once daily for 1 month
Number of subjects: 11
Study 7737713 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate reduction in salt intake (from 206 +/- 26 to 109 +/- 20 mmol urinary sodium/24 h) added to captopril for 1 month
Number of subjects: 11
Study 7737713 — intervention group
Group type: COMPARATOR
Intervention: Addition of hydrochlorothiazide
Number of subjects: 11
Study 7737713 — intervention group
Group type: COMPARATOR
Intervention: Moderate reduction in salt intake
Number of subjects: 11
Study 2149655 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 1168
Study 2149655 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 1168